Correction to: Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma

Laflamme, Philippe; Kondyli, Maria; Aljared, Tariq; Sofia, Miconiatis; Saint‐Martin, Christine; Farmer, Jean‐Pierre; Dudley, Roy; Perreault, Sébastien; Jabado, Nada; Larouche, Valérie

doi:10.1007/s11060-019-03350-5

J Neurooncol

2019

DOI: 10.1007/s11060-019-03350-5

|View full text |Cite

Correction to: Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma

Philippe Laflamme

Maria Kondyli

Tariq Aljared

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas

Erker,

Vanan,

Larouche

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Background: The treatment of BRAF V600E gliomas with BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been increasingly integrated into clinical practice for pediatric low-grade gliomas (PLGGs) and pediatric high-grade gliomas (HGGs). However, some questions remain unanswered, such as the best time to start targeted therapy, duration of treatment, and discontinuation of therapy. Given that no clinical trial has been able to address these critical questions, we developed a Canadian Consensus statement for the treatment of BRAF V600E mutated pediatric as well as adolescent and young adult (AYA) gliomas. Methods: Canadian neuro-oncologists were invited to participate in the development of this consensus. The consensus was discussed during monthly web-based national meetings, and the algorithms were revised until a consensus was achieved. Results: A total of 26 participants were involved in the development of the algorithms. Two treatment algorithms are proposed, one for the initiation of treatment and one for the discontinuation of treatment. We suggest that most patients with BRAF V600E gliomas should be treated with BRAFis ± MEKis upfront. Discontinuation of treatment can be considered in certain circumstances, and we suggest a slow wean. Conclusions: Based on expert consensus in Canada, we developed algorithms for treatment initiation of children and AYA with BRAF V600E gliomas as well as a discontinuation algorithm.

show abstract

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas

Erker,

Vanan,

Larouche

et al. 2024

Current Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Correction to: Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma

Cited by 1 publication

References 0 publications

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas

Contact Info

Product

Resources

About